Kisho

Soligenix, Inc. — Rare Disease Pipeline | Kisho | Kisho

Soligenix, Inc.

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
Behcet disease	dusquetidebeclomethasone 17,21-dipropionate	Orphan Designation	-
Castleman disease	beclomethasone 17,21-dipropionate	Orphan Designation	-
Qazi Markouizos syndrome	ricin vaccine	Orphan Designation	-
T-cell non-Hodgkin lymphoma	Hypericin	Orphan Designation	-
acute radiation syndrome	L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	Orphan Designation	-
gastrointestinal stromal tumor	beclomethasone 17,21-dipropionate	Orphan Designation	-
gastrointestinal tuberculosis	beclomethasone 17,21-dipropionate	Orphan Designation	-
glioma susceptibility 1	Hypericin	Orphan Designation	-
intestinal atresia	beclomethasone dipropionate	Orphan Designation	-
intestinal failure–associated liver disease	beclomethasone dipropionate	Orphan Designation	-
intestinal neoplasm	beclomethasone dipropionate	Orphan Designation	-
macrophage activation syndrome	dusquetide	Orphan Designation	-
pediatric hepatocellular carcinoma	beclomethasone 17,21-diproprionate	Orphan Designation	-
pediatric ovarian dysgerminoma	beclomethasone 17,21-diproprionate	Orphan Designation	-
pediatric-onset Graves disease	beclomethasone 17,21-diproprionate	Orphan Designation	-
post-thrombotic syndrome	subunit protein vaccine of recombinantly expressed Sudan Ebola virus glycoprotein	Orphan Designation	-
post-traumatic stress disorder	subunit protein vaccine of recombinantly expressed Sudan Ebola virus glycoprotein	Orphan Designation	-
post-vaccinal encephalitis	subunit protein vaccine of recombinantly expressed Sudan Ebola virus glycoprotein	Orphan Designation	-
primary cutaneous T-cell non-Hodgkin lymphoma	hypericin	Orphan Designation	-
ricin poisoning	ricin vaccine	Orphan Designation	-

← Back to Companies